CMMB— Chemomab Therapeutics Ltd.

MaterialsBiotechnology$1.6B mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Research and development	$5.8M-48.5%	$11.3M-38.4%	$18.4M+8.3%	$17.0M
General and administrative	$3.7M+9.4%	$3.4M-51.8%	$7.1M-38.8%	$11.6M
Total operating expenses	$9.6M-35.1%	$14.7M-42.1%	$25.5M-10.8%	$28.5M
Financing income, net	-$572K+28.0%	-$794K+35.9%	-$1.2M-250.7%	-$353K
Loss before income taxes	$9.0M-35.5%	$13.9M-42.4%	$24.2M-14.0%	$28.2M
Income Tax expenses	$0	$0	$0+100.0%	-$534K
Net loss for the year	$9.0M-35.5%	$13.9M-42.4%	$24.2M-12.4%	$27.6M
Basic loss per Ordinary Share	$18-53.8%	$39-62.1%	$103-14.9%	$121
Diluted loss per Ordinary Share	$18-53.8%	$39-62.1%	$103-14.9%	$121
Weighted average number of Ordinary Shares outstanding, basic	510.23B+42.1%	359.05B+52.8%	235.00B+3.3%	227.59B
Weighted average number of Ordinary Shares outstanding, diluted	510.23B+42.1%	359.05B+52.8%	235.00B+3.3%	227.59B

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 2 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.